Patent 9579234 was granted and assigned to Ivantis, Inc on February, 2017 by the United States Patent and Trademark Office.
A method of treating glaucoma in a human eye by inserting a distal exit port of a cannula at least partially into Schlemm's canal of the eye; delivering a dye through the cannula into Schlemm's canal; identifying obstructions within Schlemm's canal; and delivering an ocular implant through the cannula into Schlemm's canal.